Primary outcome 3: Adverse events · people (all patch‐tested) with hand eczema > 6 months that had cleared upon daily treatment for a maximum of 9 weeks with mometasone…
Corticosteroid creams/ointments: mometasone furoate cream 3 times/week showed no clear difference in primary: adverse events compared with 2 times/week (low certainty).
1 finding from 1 review
Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life ‐ not reported · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata
It is very uncertain whether summary of findings table ‐ Intralesional classical… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).
1 finding from 1 review
Methotrexate · people with chronic plaque psoriasis
Any systemic treatment may leads to higher methotrexate compared with placebo (low certainty).
2 findings from 1 review
Intervention not reported
Methotrexate (1 RCT; 50 participants) · patients with moderate to severe eczema
It is very uncertain whether the intervention changes methotrexate (1 RCT; 50 participants) (very low certainty).
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
Metronidazole showed no clear difference in proportion of participants with adverse event compared with placebo (high certainty).
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
Metronidazole probably leads to higher physician‐assessed improvement in rosacea severity compared with placebo (moderate certainty).
1 finding from 1 review
Assessment of erythema or telangiectasia · Participants with rosacea
1 finding from 1 review
Lesion count · Participants with rosacea
1 finding from 1 review
Time needed until improvement of the skin lesions · Participants with rosacea
1 finding from 1 review
Duration of remission · Participants with rosacea
Metronidazole probably leads to lower duration of remission compared with placebo (moderate certainty).
1 finding from 1 review
Primary outcome: complete clinical response (malar/discoid rash) · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher primary outcome: complete clinical response (malar/discoid rash) compared with placebo (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in secondary outcome: clinical flare compared with placebo (moderate certainty).
1 finding from 1 review
Complete response · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in primary outcome: complete clinical response compared with oral chloroquine (low certainty).
1 finding from 1 review
Primary outcome: partial clinical response · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review